Eleva has initiated dosing in its Phase I trial of its recombinant human complement Factor H (CPV-104) programme, for C3-glomerulopathy (C3G).

PYC Therapeutics is set to begin Part B in its SAD study of the drug candidate, PYC-003, for polycystic kidney disease (PKD) patients.

The FDA and the EMA have authorised AB Science’s confirmatory Phase III Study AB22007 trial of masitinib for mCRPC.

The HHS and the FDA have been ordered by US District Judge John Bates to restore the webpages on diversity following the court’s ruling.

The China NMPA's CDE has granted approval to the IND application of InnoCare Pharma to initiate the trial of ICP-B794.

Novartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the GCAptAIN trial (NCT04930094), ...

BioAtla has presented first-in-human Phase I study data of its anticancer therapy, BA3182, targeting those with metastatic adenocarcinoma.

Researchers investigated timelines for ethical, administrative, regulatory and logistical procedures in clinical trials across Europe.

Opioid use disorder (OUD) has become a mounting public health crisis in the US, often disproportionately affecting individuals in the most vulnerable socioeconomic statuses.

Belite Bio has completed enrolment in the 24-month PHOENIX Phase III trial assessing the tolerability and safety of oral Tinlarebant.

Ascletis Pharma has dosed the first obese or overweight subjects in the 13-week, multi-centre US Phase IIa trial of ASC30.

Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA proof-of-concept study (NCT05560646) was evaluating Organon’s therapy, ...